Polylactic acid (PLA) controlled delivery carriers for biomedical applications
B Tyler, D Gullotti, A Mangraviti, T Utsuki… - Advanced drug delivery …, 2016 - Elsevier
Polylactic acid (PLA) and its copolymers have a long history of safety in humans and an
extensive range of applications. PLA is biocompatible, biodegradable by hydrolysis and …
extensive range of applications. PLA is biocompatible, biodegradable by hydrolysis and …
[HTML][HTML] Applications of synthetic polymers in clinical medicine
MF Maitz - Biosurface and Biotribology, 2015 - Elsevier
Multiple biological, synthetic and hybrid polymers are used for multiple medical applications.
A wide range of different polymers is available, and they have further the advantage to be …
A wide range of different polymers is available, and they have further the advantage to be …
[HTML][HTML] Five-year outcomes after PCI or CABG for left main coronary disease
GW Stone, AP Kappetein, JF Sabik… - … England Journal of …, 2019 - Mass Medical Soc
Background Long-term outcomes after percutaneous coronary intervention (PCI) with
contemporary drug-eluting stents, as compared with coronary-artery bypass grafting …
contemporary drug-eluting stents, as compared with coronary-artery bypass grafting …
Everolimus-eluting stents or bypass surgery for left main coronary artery disease
GW Stone, JF Sabik, PW Serruys… - … England Journal of …, 2016 - Mass Medical Soc
Background Patients with obstructive left main coronary artery disease are usually treated
with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug …
with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug …
Expert recommendations on the assessment of wall shear stress in human coronary arteries: existing methodologies, technical considerations, and clinical …
F Gijsen, Y Katagiri, P Barlis, C Bourantas… - European heart …, 2019 - academic.oup.com
Expert recommendations on the assessment of wall shear stress in human coronary arteries:
existing methodologies, technical considerations, and clinical applications | European Heart …
existing methodologies, technical considerations, and clinical applications | European Heart …
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the …
comprehensive review of the published evidence for management of a given condition
according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of …
according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of …
Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease: meta-analysis of …
S Bangalore, B Toklu, N Patel, F Feit, GW Stone - Circulation, 2018 - Am Heart Assoc
Background: Contemporary second-generation drug-eluting stents (DES) have superior
efficacy and safety in comparison with early-generation stents in patients undergoing …
efficacy and safety in comparison with early-generation stents in patients undergoing …
Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis
T Palmerini, U Benedetto, G Biondi-Zoccai… - Journal of the American …, 2015 - jacc.org
Background: Previous meta-analyses have investigated the relative safety and efficacy
profiles of different types of drug-eluting stents (DES) and bare-metal stents (BMS); however …
profiles of different types of drug-eluting stents (DES) and bare-metal stents (BMS); however …
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation …
DE Kandzari, L Mauri, JJ Koolen, JM Massaro, G Doros… - The Lancet, 2017 - thelancet.com
Background The development of coronary drug-eluting stents has included use of new metal
alloys, changes in stent architecture, and use of bioresorbable polymers. Whether these …
alloys, changes in stent architecture, and use of bioresorbable polymers. Whether these …
Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC)
The lack of consistent definitions and nomenclature across clinical trials of novel devices,
drugs, or biologics poses a significant barrier to accrual of knowledge in and across …
drugs, or biologics poses a significant barrier to accrual of knowledge in and across …